FDA authorizes COVID-19 Omicron boosters for kids as young as 5
The U.S. Food and Drug Administration on Wednesday authorized COVID-19 Omicron booster shots for children as young as five, taking an additional step to help kids stay protected against the virus.
In a statement, the FDA said it had cleared the updated booster from Pfizer and its partner BioNTech for children ages five to 11. The agency also authorized the updated booster from Moderna for children ages six to 17.
Wednesday's news marks a continuing update on the available boosters for children, as the FDA had previously cleared the Pfizer booster for people 12 and over, and the Moderna booster for people 18 and older, per The Wall Street Journal. Children ages five to 11 could have access to the Omicron boosters "in the coming days" if the shots soon receive official clearance from the U.S. Centers for Disease Control and Prevention, the Journal added.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The FDA has continued to push vaccines for kids, particularly as winter approaches. "Since children have gone back to school in person and people are resuming pre-pandemic behaviors and activities, there is the potential for increased risk of exposure to the virus that causes COVID-19," Dr. Peter Marks told the FDA. "Vaccination remains the most effective measure to prevent the severe consequences of COVID-19."
Even as the effort to vaccinate children continues, data from the American Academy of Pediatrics cited by the Journal says that just 31 percent of kids ages five to 11 have completed their primary vaccine series.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Justin Klawans has worked as a staff writer at The Week since 2022. He began his career covering local news before joining Newsweek as a breaking news reporter, where he wrote about politics, national and global affairs, business, crime, sports, film, television and other news. Justin has also freelanced for outlets including Collider and United Press International.
-
Is the US in recession?Today's Big Question ‘Unofficial signals’ are flashing red
-
Dinosaurs were thriving before asteroid, study findsSpeed Read The dinosaurs would not have gone extinct if not for the asteroid
-
Trump pardons crypto titan who enriched familySpeed Read Binance founder Changpeng Zhao pleaded guilty in 2023 to enabling money laundering while CEO of the cryptocurrency exchange
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
Is this the end of ultraprocessed foods?Today's Big Question California law and the MAHA movement are on the same track
-
Bluetoothing: the phenomenon driving HIV spike in FijiUnder the Radar ‘Blood-swapping’ between drug users fuelling growing health crisis on Pacific island
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
‘Nightmare bacteria’ are rapidly spreadingUnder the radar The infections are largely resistant to antibiotics
-
Kissing bug disease has a growing presence in the USThe explainer The disease has yielded a steady stream of cases in the last 10 years
-
Climate change is making us eat more sugarUnder the radar Sweets make the heat feel more manageable
